Atrial fibrillation (AF) is the most prevalent arrhythmia in elderly people worldwide. With rapidly aging populations in Asia, optimizing AF outcomes is now a greater priority than ever. Novel oral anticoagulant (NOAC) therapy has been shown to reduce the risk of stroke and all-cause mortality in patients with AF, however, determining which NOAC to prescribe for individual patients based on their associated risks and benefits can be challenging.
Originally presented at the National Heart Association of Malaysia meeting 2017, in this lecture, Professor Fox examines the evidence on the differences and similarities between NOACs and shares his expert insights on how to select the right NOAC for the right patient.
Professor Keith AA Fox is a Duke of Edinburgh Professor of Cardiology at the University of Edinburgh.
Professor Fox is a founding fellow of the European Society of Cardiology and is currently Chair of the Programme of the European Society of Cardiology. His awards include the Silver Medal of the European Society of Cardiology (ESC) in 2010 and again in 2014 and the Mackenzie medal of the British Cardiovascular Society in 2013. In 2015, he gave the American Heart Association (AHA) "Paul Dudley White Lecture" at the AHA Congress in the same year was awarded the Gold Medal of the ESC.
An active researcher, Professor Fox has authored more than 460 scientific papers, with his main research interest in the mechanisms and manifestation of acute coronary arterial disease.